Form D · Biotechnology
Atommap Corp
New York, NY · CIK 0002001012
Offering snapshot reported Mar 20, 2026 · SEC filing
- Reported sold
- $31.1M Offering amount: $59.6M
- Investors reported
- 29 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 6, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 20, 2026 | Initial | $31,130,335 | No comparison | 29 | SEC filing |
| Nov 16, 2023 | Initial | $7,084,989 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-577186
Offering of Series A and Series A-1 Preferred Stock (collectively "Series A") and the underlying shares of Common Stock issuable upon conversion of Series A.
Source: Form D, filed Mar 20, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Keith Loebner | Director |
| Huafeng Xu | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1059 3 Rd Avenue Apartment 17 B
New York, NY, 10065
New York, NY, 10065